FRAX597

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

FRAX597 是 I 组 PAK 的有效 ATP 竞争性抑制剂，适用于 PAK1 (IC50=8 nM)、PAK2 (IC50=13 nM) 和 PAK3 (IC50=19 nM)。

FRAX597 is a potent and selective inhibitor of the p21-activated kinases. FRAX597 inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. FRAX597 inhibits the proliferation of NF2-deficient schwannoma cells in culture and displayed potent anti-tumor activity in vivo, impairing schwannoma development in an orthotopic model of NF2. These studies identify a novel class of orally available ATP-competitive Group I PAK inhibitors with significant potential for the treatment of NF2 and other cancers.

FRAX597 is determined to be a potent, ATP-competitive inhibitor of group I PAKs (PAK 1-3), with biochemical IC50 values as follows: PAK1 IC50=8 nM, PAK2 IC50=13 nM, PAK3 IC50=19 nM. The IC50 toward PAK4, a member of group II PAKs is >10 μM. At a concentration of 100 nM FRAX597 displays a significant (>80% inhibition) inhibitory capacity toward YES1 (87%), RET (82%), CSF1R (91%), TEK (87%), PAK1 (82%), and PAK2 (93%). When measured using the Kinase Glo Assay in the presence of 20 nM protein and 1 μM ATP, FRAX597 displayed an IC50 value of 48 nM against wild type PAK1, while IC50 values against the V342F and V342Y PAK1 mutants are higher than 3 μM and 2 μM, respectively.

Analysis of the flux reading for the animals in the two cohorts demonstrates a significantly slower tumor growth rate in FRAX597-treated mice compared with control mice. After 14 days of treatment the animals are sacrificed and the tumors excised and weighed. FRAX597-treated cohort shows significantly lower average tumor weight compared with the control cohort .

FRAX597 | FRAX-597 | FRAX 597

Angiogenesis

EGFR

PAK1| PAK2| PAK2| PAK3

Cancer

——

1286739-19-2

558.1

C29H28ClN7OS

>98% (HPLC)

DMSO : 14.29 mg/mL. 25.60 mM;H2O : < 0.1 mg/mL

CCn1c2nc(ncc2cc(c1=O)c1c(cc(cc1)c1cncs1)Cl)Nc1ccc(cc1)N1CCN(CC1)C

6-[2-chloro-4-(1,3-thiazol-5-yl)phenyl]-8-ethyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidin-7-one

(-20℃)

With Ice Pack

≥ 2 years